Published in Pharmacol Biochem Behav on July 01, 1986
Dopamine receptor modulation of repetitive grooming actions in the rat: potential relevance for Tourette syndrome. Brain Res (2010) 1.06
Evidence for the sensitivity of operant timing behaviour to stimulation of D1 dopamine receptors. Psychopharmacology (Berl) (2007) 0.83
Evidence for a role of D1 dopamine receptors in d-amphetamine's effect on timing behaviour in the free-operant psychophysical procedure. Psychopharmacology (Berl) (2006) 0.82
Effects of d-amphetamine and DOI (2,5-dimethoxy-4-iodoamphetamine) on timing behavior: interaction between D1 and 5-HT2A receptors. Psychopharmacology (Berl) (2006) 0.82
Behavioural responses to the selective D1-dopamine receptor agonist R-SK&F 38393 and the selective D2-agonist RU 24213 in young compared with aged rats. Br J Pharmacol (1988) 0.75
Risk of schizophrenia in adults born after obstetric complications and their association with early onset of illness: a controlled study. BMJ (1992) 2.03
Phenotypic characterization of an alpha 4 neuronal nicotinic acetylcholine receptor subunit knock-out mouse. J Neurosci (2000) 1.70
Identification in 2 independent samples of a novel schizophrenia risk haplotype of the dystrobrevin binding protein gene (DTNBP1). Arch Gen Psychiatry (2004) 1.60
Phenotypic characterization of spatial cognition and social behavior in mice with 'knockout' of the schizophrenia risk gene neuregulin 1. Neuroscience (2007) 1.55
Evidence for geographical variations in the prevalence of schizophrenia in rural Ireland. Arch Gen Psychiatry (1991) 1.54
[Tuberculous rheumatism, Poncet disease: a sterile controversy ?]. Rev Rhum Ed Fr (1993) 1.43
Season of birth in schizophrenia. Evidence for confinement of an excess of winter births to patients without a family history of mental disorder. Br J Psychiatry (1991) 1.29
Magnetic resonance imaging of schizophrenia-like psychoses associated with cerebral trauma: clinicopathological correlates. Am J Psychiatry (1993) 1.21
Neurochemical changes following kainic acid lesions of the nucleus accumbens: implications for a GABAergic accumbal-ventral tegmental pathway. Life Sci (1978) 1.19
Behavioural evidence for GABAergic activity of the benzodiazepine flurazepam. Eur J Pharmacol (1978) 1.14
Familial, obstetric, and other clinical correlates of minor physical anomalies in schizophrenia. Am J Psychiatry (1991) 1.14
Abnormalities of cerebral structure in schizophrenia on magnetic resonance imaging: interpretation in relation to the neurodevelopmental hypothesis. J R Soc Med (1992) 1.12
Confirmation and refinement of an 'at-risk' haplotype for schizophrenia suggests the EST cluster, Hs.97362, as a potential susceptibility gene at the Neuregulin-1 locus. Mol Psychiatry (2004) 1.08
The anthropometric assessment of dysmorphic features in schizophrenia as an index of its developmental origins. Psychol Med (1997) 1.08
Dopaminergic behaviour stereospecific promoted by the D1 agonist R-SK & F 38393 and selectively blocked by the D1 antagonist SCH 23390. Psychopharmacology (Berl) (1984) 1.06
Methodological problems in the measurement of drug-induced rotational behaviour: continuous recording reveals time-course differences undetected by previous techniques. Psychopharmacology (Berl) (1978) 1.03
Loss of rat striatal dopamine receptors with ageing is selective for D-2 but not D-1 sites: association with increased non-specific binding of the D-1 ligand [3H]piflutixol. Eur J Pharmacol (1984) 1.00
Polyarteritis nodosa following angioplasty. Ann Rheum Dis (1993) 0.99
Inter-relationships between behavioural and neurochemical indices of supersensitivity in dopaminergic neurones [proceedings]. Br J Pharmacol (1978) 0.98
Mood congruent psychotic symptoms and specific cognitive deficits in carriers of the novel schizophrenia risk variant at MIR-137. Neurosci Lett (2012) 0.98
Phenotypic characterization of cognition and social behavior in mice with heterozygous versus homozygous deletion of catechol-O-methyltransferase. Neuroscience (2008) 0.96
GABA-like properties of flurazepam and baclofen suggested by rotational behaviour following unilateral intranigral injection: a comparison with the GABA agonist muscimol [proceedings]. Br J Pharmacol (1977) 0.96
Reproductive behaviour in schizophrenia relative to other mental disorders: evidence for increased fertility in men despite decreased marital rate. Acta Psychiatr Scand (1995) 0.96
Cholinergic activation of Cl- secretion in rat colonic epithelia. Eur J Pharmacol (1995) 0.95
Denervation supersensitivity in the striatonigral GABA pathway. Nature (1978) 0.94
Induction of rotational behaviour by intranigral baclofen suggests possible GABA-agonist activity. Experientia (1977) 0.94
Obstetric complications in schizophrenia and the validity of maternal recall. Psychol Med (1990) 0.93
Grooming and vacuous chewing induced by SK&F 83959, an agonist of dopamine 'D1-like' receptors that inhibits dopamine-sensitive adenylyl cyclase. Eur J Pharmacol (1993) 0.93
Conservation of behavioural topography to dopamine D1-like receptor agonists in mutant mice lacking the D1A receptor implicates a D1-like receptor not coupled to adenylyl cyclase. Neuroscience (1999) 0.92
Topographical evaluation of behavioural phenotype in a line of mice with targeted gene deletion of the D2 dopamine receptor. Neuropharmacology (2000) 0.92
Late onset involuntary movements in chronic schizophrenia: relationship of 'tardive' dyskinesia to intellectual impairment and negative symptoms. Br J Psychiatry (1986) 0.92
Spontaneous abnormal involuntary movements in first-episode schizophrenia and schizophreniform disorder: baseline rate in a group of patients from an Irish catchment area. Am J Psychiatry (1998) 0.92
Evidence for association and epistasis at the DAOA/G30 and D-amino acid oxidase loci in an Irish schizophrenia sample. Am J Med Genet B Neuropsychiatr Genet (2007) 0.92
Role of alpha adrenoceptors in the nucleus accumbens in the control of accumbal noradrenaline efflux: a microdialysis study with freely moving rats. J Neural Transm (Vienna) (2007) 0.92
Determinants of quality of life at first presentation with schizophrenia. Br J Psychiatry (2000) 0.92
Dopamine receptor function and spontaneous orofacial dyskinesia in rats during 6-month neuroleptic treatments. Adv Biochem Psychopharmacol (1983) 0.91
Clinical symptomatology and the psychosis risk gene ZNF804A. Schizophr Res (2010) 0.91
A behavioural model of the GABA-facilitating action of benzodiazepines: rotational behaviour after unilateral intranigral injection of chloridiazepoxide [proceedings]. Br J Pharmacol (1976) 0.91
Behavioural effects of the putative D-3 dopamine receptor agonist 7-OH-DPAT in relation to other "D-2-like" agonists. Neuropharmacology (1993) 0.91
Pharmacological characterization of behavioural responses to SK&F 83959 in relation to 'D1-like' dopamine receptors not linked to adenylyl cyclase. Br J Pharmacol (1995) 0.91
Schizophrenia and neurological soft signs: gender differences in clinical correlates and antecedent factors. Psychiatry Res (1996) 0.90
The relationship of minor physical anomalies and other putative indices of developmental disturbance in schizophrenia to abnormalities of cerebral structure on magnetic resonance imaging. Biol Psychiatry (1995) 0.89
Schizophrenia, neurodevelopment, and disease. The Fifth Biannual Winter Workshop on Schizophrenia, Badgastein, Austria, January 28 to February 3, 1990. Arch Gen Psychiatry (1991) 0.88
Mice lacking the alpha4 nicotinic receptor subunit fail to modulate dopaminergic neuronal arbors and possess impaired dopamine transporter function. Mol Pharmacol (2005) 0.88
Behavioural, hyperthermic and neurotoxic effects of 3,4-methylenedioxymethamphetamine analogues in the Wistar rat. Prog Neuropsychopharmacol Biol Psychiatry (2001) 0.88
1H-magnetic resonance spectroscopy of the left temporal and frontal lobes in schizophrenia: clinical, neurodevelopmental, and cognitive correlates. Biol Psychiatry (1994) 0.88
Spontaneous orofacial dyskinesia and dopaminergic function in rats after 6 months of neuroleptic treatment. Science (1983) 0.88
Essential fatty acids given from conception prevent topographies of motor deficit in a transgenic model of Huntington's disease. Neuroscience (2002) 0.88
Schizophrenia-related endophenotypes in heterozygous neuregulin-1 'knockout' mice. Eur J Neurosci (2010) 0.88
Abnormal involuntary movements in schizophrenia: are they related to the disease process or its treatment? Are they associated with changes in dopamine receptors? J Clin Psychopharmacol (1982) 0.88
Baclofen and muscimol: behavioural and neurochemical sequelae of unilateral intranigral administration and effects on 3H-GABA receptor binding. Naunyn Schmiedebergs Arch Pharmacol (1979) 0.88
Determinants of neurological dysfunction in first episode schizophrenia. Psychol Med (2000) 0.87
Resting heartrate variability in man declines with age. Experientia (1979) 0.86
Assessment of grooming and other behavioural responses to the D-1 dopamine receptor agonist SK & F 38393 and its R- and S-enantiomers in the intact adult rat. Psychopharmacology (Berl) (1987) 0.86
Geographical variation in rate of schizophrenia in rural Ireland by place at birth vs place at onset. Schizophr Res (1999) 0.85
Primitive (developmental) reflexes and diffuse cerebral dysfunction in schizophrenia and bipolar affective disorder: overrepresentation in patients with tardive dyskinesia. Biol Psychiatry (1988) 0.85
'Early-onset schizophrenia' after teenage head injury. A case report with magnetic resonance imaging. Br J Psychiatry (1988) 0.85
Topographical assessment and pharmacological characterization of orofacial movements in mice: dopamine D(1)-like vs. D(2)-like receptor regulation. Eur J Pharmacol (2001) 0.85
Adenosine A1 receptor-mediated inhibition of dopamine release from rat striatal slices is modulated by D1 dopamine receptors. Eur J Neurosci (2007) 0.85
Comparative, topographically-based evaluation of behavioural phenotype and specification of D(1)-like:D(2) interactions in a line of incipient congenic mice with D(2) dopamine receptor 'knockout'. Neuropsychopharmacology (2001) 0.84
Disruption of exploratory and habituation behavior in mice with mutation of DISC1: an ethologically based analysis. J Neurosci Res (2012) 0.84
Topographical evaluation of the phenotype of spontaneous behaviour in mice with targeted gene deletion of the D1A dopamine receptor: paradoxical elevation of grooming syntax. Neuropharmacology (1998) 0.84
Topographically based search for an "Ethogram" among a series of novel D(4) dopamine receptor agonists and antagonists. Neuropsychopharmacology (2000) 0.84
Agonist and antagonist properties of benzazepine and thienopyridine derivatives at the D1 dopamine receptor. Neuropharmacology (1989) 0.84
D2 receptor antagonists do not modify guanine nucleotide-sensitive interactions between dopamine and D1 dopamine receptors under in vitro conditions. J Neurochem (1995) 0.83
Behavioural pharmacology of 'D-1-like' dopamine receptors: further subtyping, new pharmacological probes and interactions with 'D-2-like' receptors. Prog Neuropsychopharmacol Biol Psychiatry (1995) 0.83
Effects of the putative D-1 antagonist SCH 23390 on stereotyped behaviour induced by the D-2 agonist RU24213. Psychopharmacology (Berl) (1985) 0.83
The interaction of clozapine with dopamine D1 versus dopamine D2 receptor-mediated function: behavioural indices. Eur J Pharmacol (1990) 0.82
The clinical correlates of neurological soft signs in chronic schizophrenia. Br J Psychiatry (1991) 0.82
Obstetric complications, the putative familial-sporadic distinction, and tardive dyskinesia in schizophrenia. Br J Psychiatry (1990) 0.82
Selective and stereospecific interactions of R-SK & F 38393 with [3H]piflutixol but not [3H]spiperone binding to striatal D1 and D2 dopamine receptors: comparisons with SCH 23390. Eur J Pharmacol (1984) 0.82
Prospective evaluation of neurological soft signs in first-episode schizophrenia in relation to psychopathology: state versus trait phenomena. Psychol Med (2003) 0.81
Behavioural evidence for "D-1-like" dopamine receptor subtypes in rat brain using the new isochroman agonist A 68930 and isoquinoline antagonist BW 737C. Psychopharmacology (Berl) (1993) 0.81
Behavioural correlates of the action of selective D-1 dopamine receptor antagonists. Impact of SCH 23390 and SKF 83566, and functionally interactive D-1:D-2 receptor systems. Biochem Pharmacol (1986) 0.81
Dopaminergic mechanisms and cognitive deficit in schizophrenia. A neurobiological model. Psychopharmacology (Berl) (1979) 0.81
Late onset involuntary movements in chronic schizophrenia: age-related vulnerability to 'tardive' dyskinesia independent of extent of neuroleptic medication. Ir Med J (1985) 0.81
Psychopathology, executive (frontal) and general cognitive impairment in relation to duration of initially untreated versus subsequently treated psychosis in chronic schizophrenia. Psychol Med (1997) 0.80
Diagnostic trajectory, interplay and convergence/divergence across all 12 DSM-IV psychotic diagnoses: 6-year follow-up of the Cavan-Monaghan First Episode Psychosis Study (CAMFEPS). Psychol Med (2013) 0.80
[3H] Quinuclidinyl benzylate and [3H] GABA receptor binding in rat substantia nigra after 6-hydroxy-dopamine lesions. Neurosci Lett (1980) 0.80
Neuroendocrine mechanisms and the aetiology of male and female homosexuality. Br J Psychiatry (1981) 0.80
D-amphetamine and antipsychotic drug effects on latent inhibition in mice lacking dopamine D2 receptors. Neuropsychopharmacology (2013) 0.80
The induction of grooming and vacuous chewing by a series of selective D-1 dopamine receptor agonists: two directions of D-1:D-2 interaction. Eur J Pharmacol (1989) 0.80
Vulnerability to involuntary movements over a lifetime trajectory of schizophrenia approaches 100%, in association with executive (frontal) dysfunction. Schizophr Res (2001) 0.80
Drugs acting on brain dopamine receptors: a conceptual re-evaluation five years after the first selective D-1 antagonist. Pharmacol Ther (1989) 0.80
Sniffing, rearing and locomotor responses to the D-1 dopamine agonist R-SK&F 38393 and to apomorphine: differential interactions with the selective D-1 and D-2 antagonists SCH 23390 and metoclopramide. Eur J Pharmacol (1985) 0.80
Characterization of abnormal respiratory movements in schizophrenic, bipolar and mentally handicapped patients with typical tardive dyskinesia. Int Clin Psychopharmacol (1989) 0.79
Functional coupling of a recombinant human 5-HT5A receptor to G-proteins in HEK-293 cells. Br J Pharmacol (1998) 0.79
Effects of nomifensine and desipramine on the sequelae of intracerebrally-injected 6-OHDA and 5,6-DHT. Pharmacol Biochem Behav (1980) 0.79
[3H]R05-4864 and [3H]flunitrazepam binding in kainate-lesioned rat striatum and in temporal cortex of brains from patients with senile dementia of the Alzheimer type. Brain Res (1983) 0.79
Further evidence for two directions of D-1:D-2 dopamine receptor interaction revealed concurrently in distinct elements of typical and atypical behaviour: studies with the new enantioselective D-2 agonist LY 163502. Psychopharmacology (Berl) (1989) 0.79
[3H]SCH 23390 binding to human putamen D-1 dopamine receptors: stereochemical and structure-affinity relationships among 1-phenyl-1H-3-benzazepine derivatives as a guide to D-1 receptor topography. J Neurochem (1987) 0.79